NCT06013839View on ClinicalTrials.gov

TXA127 in Non-Ambulant Patients With DMD Cardiomyopathy

PHASE2UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

August 31, 2024

Study Completion Date

December 31, 2024

Conditions
DMD-Associated Dilated Cardiomyopathy
Interventions
DRUG

talfirastide

TXA127 (talfirastide) is a pharmaceutically formulated angiotensin (1-7) heptapeptide, identical to the endogenously produced, non-hypertensive derivative of angiotensin II (Ang II).

Trial Locations (2)

Unknown

RECRUITING

Hadassah Medical Center, Jerusalem

RECRUITING

Sheba Medical Center, Ramat Gan

Sponsors
All Listed Sponsors
lead

Constant Therapeutics LLC

INDUSTRY

NCT06013839 - TXA127 in Non-Ambulant Patients With DMD Cardiomyopathy | Biotech Hunter | Biotech Hunter